The side effects and mitigation methods of the Laotian version of Infiglatinib
Infiglatinib, as an FGFR inhibitor, commonly has side effects such as eye, skin, and electrolyte imbalances. Targeted monitoring and intervention measures are needed to ensure medication safety. Below is a detailed explanation of the classification of side effects and mitigation methods.
1. Common side effects and treatment
(1) Eye problems: Possible detachment of retinal pigment epithelium or blurred vision. It is recommended to have regular eye examinations before and during treatment. If there is a flashing sensation or visual field defect, stop medication immediately and seek medical attention.
(2) Skin reactions: About 72.5% of patients develop nail diseases, and 49.3% experience redness and swelling of the palms and soles. Keep the skin of hands and feet moist, avoid mechanical friction, and use corticosteroid ointment in severe cases.
(3) Electrolyte imbalance: common hypophosphatemia. It is necessary to monitor blood phosphorus levels weekly, supplement phosphate preparations if necessary, and adjust diet to increase dairy product intake.
2. Adverse reactions in the blood system
(1) Thrombocytopenia: Avoid vigorous exercise and the use of sharp tools, use a soft bristled toothbrush, and observe abnormal bleeding signs such as black stool or hematuria.
(2) Anemia: Regularly test for hemoglobin, consider erythropoietin treatment in severe cases, and supplement with iron and folic acid.
3. Special risk prevention
(1) Photogenic reaction: Strict sun protection measures, use SPF50+sunscreen, wear protective clothing, and avoid exposure to ultraviolet devices.
(2) Embryotoxicity: Patients of childbearing age should take effective contraceptive measures during treatment and within one month after discontinuing medication, and confirm pregnancy status before medication.
4. Systematic management recommendations
(1) Liver function monitoring: ALT/AST should be checked monthly. If jaundice or abdominal pain occurs, immediate evaluation is required, and dosage adjustment is needed for moderate to severe liver damage.
(2) Drug interactions: Avoid the use of strong CYP3A4 inducers/inhibitors in combination, and adjust the dosage of infliximab if necessary.
Disclaimer：《The side effects and mitigation methods of the Laotian version of Infiglatinib》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！